Theravance (THRX) Anoro COPD Studies Gives Baird Increased Confidence
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
Go back to Theravance (THRX) Anoro COPD Studies Gives Baird Increased Confidence
March 14, 2014 10:07 AM EDT
GlaxoSmithKline plc (NYSE: GSK) and Theravance's (NASDAQ: THRX) Breo Ellipta sales are well below estimates, said Leerink Swann, cited IMS data. Scripts were roughly flat at 1,634 last week. Analyst Howard Liang said "significant acceleration" is needed to meet... More
March 13, 2014 8:05 AM EDT
GlaxoSmithKline plc (NYSE: GSK) and Theravance, Inc. (Nasdaq: THRX) announced that recruitment of patients into the "Study to Understand Mortality and MorbidITy", known as SUMMIT, has completed enrolment. The aim of this study, which has now enrolled approximately 16,000 patients, is to determine the impact of Relvar/Breo Ellipta (fluticasone furoate 'FF'/vilanterol 'VI') on all cause mortality amongst patients with moderate chronic obstructive pulmonary disease (COPD) who have cardiovascular... More
